Covid makes Astrazeneca toast, but the “low cost” vaccine stops the race

In the era of the pandemic, pharmaceutical companies are kissed by the goddess of balance sheets. Last case, in chronological order, the Anglo-Swedish giant AstraZeneca: toast to super accounts even if the “low cost” vaccine resulted in reduced revenues. At the halfway point, the Oxford multinational, among the first to develop an anti-Covid drug, recorded a 23% growth in revenues, over 15 billion dollars. In the second quarter alone, when the vaccination campaigns went live, the revenues …